

## Stereospecific bioactions of 5-hydroxyicosatetraenoate

Adriano G. Rossi, Michael J. Thomas<sup>+</sup> and Joseph T. O'Flaherty

Departments of Medicine and <sup>+</sup>Biochemistry, Wake Forest University Medical Center, Winston-Salem, NC 27103, USA

Received 14 September 1988

5(*S*)-Hydroxyicosatetraenoate stimulates human polymorphonuclear neutrophils (PMNs) to raise their cytosolic calcium. It also potentiates the cells' degranulation responses to platelet-activating factor and diacylglycerols. We synthesized 5(*R*)-hydroxyicosatetraenoate and found it to be 20–100-fold weaker than the natural isomer in these assays. Thus, the arachidonic acid metabolite activates PMNs by a stereospecific possibly receptor-mediated mechanism.

5-Hydroxyicosatetraenoate; cellular  $\text{Ca}^{2+}$ ; Degranulation; Polymorphonuclear neutrophil

### 1. INTRODUCTION

Stimulated human polymorphonuclear neutrophils (PMNs) rapidly metabolize their resident phospholipids into a series of signaling molecules [1]. They release arachidonate from phospholipids and oxygenate it to 5(*S*)-HETE and  $\text{LTB}_4$ ; deacylate 1-*O*-alkyl-2-acyl-GPC and acetylate the lyso intermediate forming PAF; and cleave phosphatidylinositol and phosphatidylcholine at the *sn*-3 position to yield diacylglycerol [2–4].  $\text{LTB}_4$ , PAF and diacylglycerol directly stimulate a number of PMN responses such as degranulation and superoxide anion generation by binding to specific receptors (the receptor for diacylglycerol is protein kinase C). 5(*S*)-HETE, contrastingly, lacks appreciable intrinsic-activity in these assays. However, it does enhance the potency and power of PAF and diacylglycerol in stimulating function

[5–8]. Thus, 5(*S*)-HETE may play a unique role in stimulus-response coupling by regulating the efficacy of its companion (i.e., concurrently formed) mediators. The mechanisms involved in these bioactions of 5(*S*)-HETE, therefore, are of particular interest. Recently, 5(*S*)-HETE has been shown to stimulate calcium mobilization in PMNs [8,9]. This effect, which does not require the presence of a second mediator, appears at least partly responsible for 5(*S*)-HETE-induced potentiation of PMN responses to PAF and diacylglycerol. Nevertheless, important questions about the bioactions of 5-HETE still remain unanswered. Among these are uncertainties about structural specificity. It is known that 15-hydroxyicosatetraenoate is bioinactive whereas 5,20-dihydroxyicosatetraenoate and 5,15-dihydroxyicosatetraenoate are 30-fold and 100-fold, respectively, weaker than 5(*S*)-HETE [6,8–10]. However, these compounds differ from 5(*S*)-HETE not only in hydroxy residues but also in the positions and geometries of their double bonds, their 3-dimensional foldings, and their aqueous solubilities. Unlike 5(*S*)-HETE, they may not enter PMNs to any appreciable extent [10]. Ideal structural comparisons should be made with compounds more closely matched in physicochemical characteristics. Accordingly, we have prepared and assessed the bioactivity of 5(*R*)-HETE.

*Correspondence address:* A.G. Rossi, Department of Medicine, Division of Infectious Diseases, Wake Forest University Medical Center, Winston-Salem, NC 27103, USA

*Abbreviations:* 5(*S*)-HETE, 5(*S*)-hydroxy-6,8,11,14-*E,Z,Z,Z*-eicosatetraenoate; 5(*R*)-HETE, 5(*R*)-hydroxy-6,8,11,14-*E,Z,Z,Z*-eicosatetraenoate;  $\text{LTB}_4$ , leukotriene  $\text{B}_4$ ; PAF, platelet-activating factor; PMA, 4 $\beta$ -phorbol-12-myristate-13-acetate;  $\text{diC}_8$ , 1,2-dioctanoylglycerol; BSA, bovine serum albumin;  $[\text{Ca}^{2+}]_i$ , cytosolic free  $\text{Ca}^{2+}$  concentration

## 2. MATERIALS AND METHODS

### 2.1. Reagents and buffers

Arachidonic acid (Nu-Chek, Elysian, MN); trichloromethylchloroformate (Fluka, Buchs, Switzerland); cytochalasin B and fatty acid-free BSA (Sigma, St. Louis, MO); Fura-2 pentapotassium salt and Fura-2 acetoxymethyl ester and  $\text{diC}_8$  (Molecular Probes, Junction City, OR); and 1,5-diazabicyclo[5.4.0]undecene, dehydroabietylamine, trichlorosilane, triethylamine and 4-dimethylaminopyridine (Aldrich, Milwaukee, WI) were purchased from the indicated vendors; PAF was obtained as previously described [5]. All dilutions of 5(*S*)-HETE, 5(*R*)-HETE, PAF and  $\text{diC}_8$  were made in a modified [5] Hanks' buffer containing fatty acid-free BSA (2.5 mg/ml). Dilutions of PMA were made in dimethylsulphoxide (DMSO). The final concentration of DMSO in samples was 0.5%.

### 2.2. Preparation of 5(*S*)- and 5(*R*)-HETEs

The stereoisomers of 5-HETE were prepared by the procedure of Corey and Hashimoto [11] with the following changes: (i) trichloromethylchloroformate was used as a substitute for phosgene gas to prepare isocyanates of the 5-HETEs and (ii) the diastereomeric urethane derivatives of 5-HETE methyl ester were separated by normal phase HPLC [hexane/isopropanol/glacial acetic acid (995:4:1, v/v), 3 ml/min;  $0.75 \times 30 \mu\text{m}$ -Porasil column]. Products were identified, analyzed and checked for purity by TLC; normal and reverse-phase HPLC [10]; ultraviolet, infrared and nuclear magnetic resonance spectroscopy; and polarimetry (i.e., the

more polar carbamate, which yielded the 5(*S*)-HETE enantiomer, had a rotation of  $[\alpha]_D^{25} + 42.7^\circ$  [ $c = 1.4$ , benzene] and the less polar carbamate, which yielded the 5(*R*)-HETE, had a rotation of  $[\alpha]_D^{25} + 6.6^\circ$  [ $c = 2.4$ , benzene]).

### 2.3. Degranulation assay

Cells ( $1.3 \times 10^6$ ) were incubated in 0.5 ml buffer (37°C; 1.4 mM  $\text{CaCl}_2$ ) for 20 min; treated with 2.5  $\mu\text{g}$  cytochalasin B for 2–4 min; and challenged simultaneously with varying concentrations of the stimuli (PAF, PMA or  $\text{diC}_8$ ) plus either 5(*S*)-HETE or 5(*R*)-HETE for 5 or 15 min. The samples were placed on ice, centrifuged and the supernatant fluid assayed for lysozyme (EC 3.2.1.17) and  $\beta$ -glucuronidase (EC 3.2.1.21) as described [5]. Results are reported as net enzyme release ( $\pm$  SE), i.e., the percentage of total enzyme released by stimulated cells minus that released by unstimulated, but otherwise identically treated, cells.

### 2.4. Cytosolic calcium measurements

PMNs were loaded with Fura-2 acetoxymethyl ester, washed, and then stimulated [8]. Results are reported as the mean  $\pm$  SE of the maximal fluorescence emission ratio (340/380 nm).

## 3. RESULTS AND DISCUSSION

In agreement with previous observations [5], 5(*S*)-HETE (5–500 nM) did not induce PMNs to




Fig. 1. The effect of 5-HETE stereoisomers on PAF-induced net release of lysozyme (upper panels) and  $\beta$ -glucuronidase (lower panels) by PMNs. Shaded bars represent responses elicited by PAF alone; adjacent unshaded bars give the responses induced by PAF in the presence of increasing concentrations of 5(*S*)-HETE (left panels) and 5(*R*)-HETE (right panels). Cells ( $1.3 \times 10^6/0.5$  ml) were preincubated with 1.4 mM  $\text{CaCl}_2$  for 20 min, treated with 2.5  $\mu\text{g}$  cytochalasin B, and then challenged simultaneously with PAF and 5(*S*)-HETE or 5(*R*)-HETE. Results are reported as the mean  $\pm$  SE for 10–13 separate experiments. Note that the concentrations for 5(*S*)-HETE (left panels) are 10-fold higher than those of 5(*R*)-HETE (right panels).

Table 1

Effect of 5-HETE stereoisomers on the PMN degranulation response to PMA and diC<sub>8</sub><sup>a</sup>

Stimulus (nM)	5(S)-HETE (μM)			5(R)-HETE (μM)	
	0	0.05	5.0	0.5	5.0
PMA (1)	18.8 ± 0.9 <sup>b</sup>	24.1 ± 2.2 <sup>c</sup>	28.3 ± 2.2 <sup>c</sup>	21.9 ± 1.8	22.6 ± 2.4
PMA (3.2)	22.7 ± 2.3	27.7 ± 1.0 <sup>c</sup>	31.9 ± 0.7 <sup>c</sup>	25.1 ± 0.8	25.9 ± 3.3
diC <sub>8</sub> (3200)	2.5 ± 1.8	2.1 ± 1.3	9.8 ± 2.4 <sup>c</sup>	2.8 ± 1.8	1.7 ± 0.9
diC <sub>8</sub> (10000)	7.6 ± 1.5	7.6 ± 1.2	14.6 ± 1.3 <sup>c</sup>	6.0 ± 1.6	11.3 ± 1.0 <sup>c</sup>

<sup>a</sup> PMNs ( $1.3 \times 10^6/0.5$  ml of buffer) were incubated with cytochalasin B (2.5 μg) for 2–4 min and then challenged for 15 min with the indicated concentrations of stimulus and 5-HETE stereoisomer

<sup>b</sup> Net lysozyme release ± SE for 3–4 separate experiments. The two 5-HETE preparations similarly influenced release of β-glucuronidase

<sup>c</sup> Indicates values that are significantly ( $p < 0.05$ , Student's paired *t*-test) higher than those found in cells treated with stimulus alone

release their granule-bound enzymes. 5(R)-HETE (50–5000 nM) was likewise without effect. However, as depicted in the two left panels of fig.1, both compounds produced a substantial enhancement of PAF-induced degranulation. The potentiating effects of the unnatural stereoisomer, 5(R)-HETE, however, were >20–100-fold weaker than those elicited by 5(S)-HETE. The 5-HETE stereoisomers demonstrated similar potency differences in enhancing the PMN-degranulating actions of two protein kinase C activators, PMA and diC<sub>8</sub> (table 1).

Fig.2 illustrates the effect of the 5-HETE stereoisomers on the maximal fluorescence emission ratio (340/380 nm), a direct measurement of  $[Ca^{2+}]_i$  in Fura-2-loaded PMN. We previously reported that the biosynthetic 5(S)-HETE, at 5 μM, elevated  $[Ca^{2+}]_i$  from basal levels (~80 nM) to around 250–350 nM within 15 s. After 15 s,  $[Ca^{2+}]_i$  declined and reached pre-stimulatory levels in 2.5–5 min [8,9]. Similar calcium transients were observed with the chemically synthesized 5-HETEs (not shown). 5(S)-HETE, however, was again ~20–50-fold more potent than 5(R)-HETE in inducing the response.

Our technique for synthesizing 5-HETE stereoisomers required resolving a diastereomeric mixture of carbamylated 5-HETEs into respective precursors of 5(S)- and 5(R)-HETE by HPLC. This step did not afford perfect resolution: the final products may be cross-contaminated by 1–3%. The bioactions of 5(R)-HETE found here, therefore, may reflect this cross-contamination. (A

racemic mixture of 5-HETE was almost as potent as 5(S)-HETE. Hence, 5(R)-HETE did not inhibit 5(S)-HETE.) In any event, our results indicate that 5(S)-HETE is at least 20–100-fold more potent than 5(R)-HETE. This suggests that the various actions of 5(S)-HETE may proceed via a common, stereospecific, and possibly receptor-mediated mechanism. We have accumulated other evidence favoring this: the receptor uncoupling agent, pertussis toxin, inhibits the calcium mobilizing actions of 5(S)-HETE; and 5(S)-HETE, while down-regulating PMNs to a second 5(S)-HETE challenge, does not similarly down-regulate




Fig.2. The effect of 5(S)-HETE (circles) and 5(R)-HETE (squares) on the maximal fluorescence emission ratio (340/380 nm) of Fura-2-loaded PMNs. Each point represents the mean ± SE for 5–8 separate experiments.

responses to LTB<sub>4</sub> or PAF in the calcium mobilizing assay [9]. However, the receptor hypothesis obviously needs more direct support. We have examined PMNs and PMN membranes for the specific binding of [<sup>3</sup>H]5(S)-HETE and [<sup>3</sup>H]5(S)-HETE methyl ester. Unfortunately, the preparations rapidly and quantitatively metabolized both ligands even at 4°C. This has completely interfered with our binding assessment. Nevertheless, the results reported here support further efforts to define the putative 5(S)-HETE receptor. Given the unique bioactions expressed by 5(S)-HETE, such receptors seem sure to have novel transduction mechanisms and influences upon the PAF- and diacylglycerol-induced intracellular events promoting function.

*Acknowledgements:* This work was supported by NIH grants HL-26257 and HL-27799. We thank Vickie Cox for preparing the manuscript.

## REFERENCES

- [1] O'Flaherty, J.T. (1987) *Biochem. Pharmacol.* 36, 407–412.
- [2] Johnson, M., Carey, F. and McMillan, R.M. (1983) *Essays Biochem.* 19, 40–141.
- [3] Braquet, P., Touqui, L., Shen, T.Y. and Vargaftig, B.B. (1987) *Pharmacol. Rev.* 39, 97–145.
- [4] Abdel-Latif, A.A. (1986) *Pharmacol. Rev.* 38, 227–272.
- [5] O'Flaherty, J.T., Thomas, M.J., Hammett, M.J., Carroll, C., McCall, C.E. and Wykle, R.L. (1983) *Biochem. Biophys. Res. Commun.* 111, 1–7.
- [6] O'Flaherty, J.T., Schmitt, J.D. and Wykle, R.L. (1985) *Biochem. Biophys. Res. Commun.* 127, 916–923.
- [7] Badwey, J.A., Robinson, J.M., Horn, W., Soberman, R.J., Karnovsky, M.J. and Karnovsky, M.L. (1988) *J. Biol. Chem.* 263, 2779–2786.
- [8] O'Flaherty, J.T. and Nishihara, J. (1987) *Biochem. Biophys. Res. Commun.* 148, 575–581.
- [9] O'Flaherty, J.T., Jacobson, D. and Redman, J. (1988) *J. Immunol.* 140, 4323–4328.
- [10] O'Flaherty, J.T., Wykle, R.L., Redman, J., Samuel, M. and Thomas, M. (1986) *J. Immunol.* 137, 3277–3283.
- [11] Corey, E.J. and Hashimoto, S. (1981) *Tetrahedron Lett.* 22, 299–302.